Two inherited diseases in the carnitine biosynthetic pathway have been reported (deficiency of 6- N -trimethyllysine dioxygenase and deficiency of -butyrobetaine dioxygenase), which result in only mildly decreased to normal carnitine levels in the affected patients [60, 61]
Retatrutide, on the other hand, stands as a potent triple-agonist, orchestrating significant weight loss and glycemic control through its comprehensive action on GIP, GLP-1, and glucagon receptors
It looks at their individual mechanisms, receptor activity, effects, and possible side effects to help researchers better understand their use in pigmentation, metabolism, and other related studies
However, there is considerable individual variation, and many patients notice little change initially